Alaunos Therapeutics Inc. [TCRT] fell -6.42% so far this year. What now?

Alaunos Therapeutics Inc. [NASDAQ: TCRT] traded at a high on 11/17/22, posting a 13.26 gain after which it closed the day’ session at $1.02. The company report on November 14, 2022 that Alaunos Therapeutics Reports Third Quarter 2022 Financial Results.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON).

Actively enrolling patients in TCR-T Library Phase 1/2 trial at the second dose level; expect to treat next patient in 4Q22.

The results of the trading session contributed to over 2535005 shares changing hands. Over the past one week, the price volatility of Alaunos Therapeutics Inc. stands at 14.64% while the volatility over the past one month is 10.52%.

The market cap for TCRT stock reached $218.45 million, with 215.00 million shares outstanding and 194.54 million shares in the current float. Compared to the average trading volume of 3.77M shares, TCRT reached a trading volume of 2535005 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Alaunos Therapeutics Inc. [TCRT]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TCRT shares is $4.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TCRT stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wells Fargo have made an estimate for Alaunos Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 04, 2022.

The Average True Range (ATR) for Alaunos Therapeutics Inc. is set at 0.12, with the Price to Sales ratio for TCRT stock in the period of the last 12 months amounting to 546.13. The Price to Book ratio for the last quarter was 5.37, with the Price to Cash per share for the same quarter was set at 0.28.

How has TCRT stock performed recently?

Alaunos Therapeutics Inc. [TCRT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.67. With this latest performance, TCRT shares dropped by -7.27% in over the last four-week period, additionally plugging by 111.79% over the last 6 months – not to mention a drop of -25.00% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TCRT stock in for the last two-week period is set at 40.71, with the RSI for the last a single of trading hit 43.52, and the three-weeks RSI is set at 40.76 for Alaunos Therapeutics Inc. [TCRT]. The present Moving Average for the last 50 days of trading for this stock 1.6045, while it was recorded at 1.0061 for the last single week of trading, and 1.1823 for the last 200 days.

Alaunos Therapeutics Inc. [TCRT]: Deeper insight into the fundamentals

Alaunos Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.30 and a Current Ratio set at 2.30.

Insider trade positions for Alaunos Therapeutics Inc. [TCRT]

There are presently around $76 million, or 36.60% of TCRT stock, in the hands of institutional investors. The top three institutional holders of TCRT stocks are: MSD PARTNERS, L.P. with ownership of 15,151,516, which is approximately 0% of the company’s market cap and around 1.50% of the total institutional ownership; DISCOVERY CAPITAL MANAGEMENT, LLC / CT, holding 14,642,959 shares of the stock with an approximate value of $14.94 million in TCRT stocks shares; and VANGUARD GROUP INC, currently with $9.35 million in TCRT stock with ownership of nearly -1.434% of the company’s market capitalization.

Positions in Alaunos Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 54 institutional holders increased their position in Alaunos Therapeutics Inc. [NASDAQ:TCRT] by around 8,923,863 shares. Additionally, 51 investors decreased positions by around 8,180,412 shares, while 43 investors held positions by with 57,340,981 shares. The mentioned changes placed institutional holdings at 74,445,256 shares, according to the latest SEC report filing. TCRT stock had 20 new institutional investments in for a total of 2,816,719 shares, while 21 institutional investors sold positions of 4,099,309 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here